Literature DB >> 10347556

Loss of heterozygosity of 14q32 in colorectal carcinoma.

T Bando1, Y Kato, Y Ihara, F Yamagishi, K Tsukada, M Isobe.   

Abstract

Previous allelotyping studies on colorectal carcinoma suggest that loss of heterozygosity (LOH) on chromosome 14q may be a common genetic alteration in this tumor type. The purpose of this study was to determine precise frequency of LOH at 14q32 region in colorectal carcinomas and to define a minimal region of LOH. LOH at 14q32 in 66 primary colorectal carcinomas were analyzed by polymerase chain reaction-based deletion mapping using six highly polymorphic microsatellites. The average rate of informative data was 68.2% in all cases of colorectal carcinoma analyzed. The average rate of LOH at 14q32 was 44.1%, with the highest frequency of 50.0% at D14S267 locus in the informative cases. The minimal region of LOH was defined by markers D14S65 and D14S250 at 14q32. The present data provide useful information for the isolation of tumor suppressor genes from this region.

Entities:  

Mesh:

Year:  1999        PMID: 10347556     DOI: 10.1016/s0165-4608(98)00242-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  16 in total

1.  Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q.

Authors:  F Al-Mulla; S AlFadhli; A H Al-Hakim; J J Going; M S Bitar
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

2.  A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth.

Authors:  Xingwen Wang; Li Li; Kunming Zhao; Qingyu Lin; Huayi Li; Xuting Xue; Wenjie Ge; Hongjuan He; Dong Liu; Hui Xie; Qiong Wu; Ying Hu
Journal:  Cell Death Differ       Date:  2019-11-07       Impact factor: 15.828

Review 3.  MEG3 noncoding RNA: a tumor suppressor.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  J Mol Endocrinol       Date:  2012-04-02       Impact factor: 5.098

Review 4.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

5.  Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval.

Authors:  Yuan-Chang Dai; Chung-Liang Ho; Yi-Chang Tsai; Yung-Hsiang Hsu; Yu-Chuang Chang; Hsiao-Sheng Liu; Helen Hai-Wen Chen; Nan-Haw Chow
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-21       Impact factor: 4.553

6.  Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers.

Authors:  Bruce M Brenner; Daniel L Stoler; Luz Rodriguez; Matthew J Karpenko; Helen Swede; Nicholas J Petrelli; Garth R Anderson
Journal:  Cancer Genet Cytogenet       Date:  2007-04-01

7.  Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior.

Authors:  Zhenye Li; Chuzhong Li; Chunhui Liu; Shengyuan Yu; Yazhuo Zhang
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

8.  Loss of heterozygosity at chromosome 14q is associated with poor prognosis in head and neck squamous cell carcinomas.

Authors:  Davut Pehlivan; Esra Gunduz; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Beyhan Cengiz; Rosario S Rivera; Kunihiro Fukushima; Sukru Palanduz; Sukru Ozturk; Noboru Yamanaka; Kenji Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-03       Impact factor: 4.553

9.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Authors:  Aoife J Lowery; Nicola Miller; Amanda Devaney; Roisin E McNeill; Pamela A Davoren; Christophe Lemetre; Vladimir Benes; Sabine Schmidt; Jonathon Blake; Graham Ball; Michael J Kerin
Journal:  Breast Cancer Res       Date:  2009-05-11       Impact factor: 6.466

10.  DICER1 and PRKRA in Colon Adenocarcinoma.

Authors:  S Chiosea; M Acquafondata; J Luo; Sf Kuan; Rr Seethala
Journal:  Biomark Insights       Date:  2008-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.